Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614198 | 1.00 | KLK5 (0.56) | KLK5ATMBCHEBACE1PSEN1 | |
| SCHEMBL10722184 | 0.87 | BCHE (0.61) | KLK5ATMBCHEBACE1PSEN1 | |
| SCHEMBL28755813 | 0.87 | KLK5 (0.58) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL30318975 | 0.87 | BCHE (0.61) | KLK5ATMBCHEBACE1PSEN1 | |
| SCHEMBL5438911 | 0.86 | KLK5 (0.57) | KLK5ATMBCHEBACE1PSEN1 | |
| SCHEMBL8538004 | 0.85 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL8539590 | 0.85 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6778243 | 0.85 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL4972231 | 0.85 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6814907 | 0.85 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | KLK5 1308/4885ATM 2313/4885BCHE 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.